Research Papers
This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.
Tag: Drug Discovery
Displaying 52 papers
Acid Resistance in Mycobacterium tuberculosis
Publication: Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.
5/2009
Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug PA-824
Publication: Thompson AM, Blaser A, Anderson RF, et. al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J
2/2009
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis
Publication: Rosenthal IM, Tasneen R, Peloquin CA, et. al. Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2012 Aug; 56(8): 4331–4340. doi: 10.1128/AAC.00912-12
2/2009
Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment
Publication: Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1
11/2008
Emerging Drugs for Active Tuberculosis
Publication: Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706.
10/2008
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
Publication: Wang H, Ruan Z, Li JJ, et. al. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.
5/2008
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery
Publication: Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2
6/2007
Antimycobacterium Agents
Publication: Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.
1/2007
Novel targets for tuberculosis drug discovery
Publication: Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol. 2006 Oct;6(5):459-67. http://www.sciencedirect.com/science/article/pii/S1471489206001354. Accessed March 7, 2016
10/2006
Tuberculosis drug development pipeline: progress and hope
Publication: Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet. 2006 Mar 18;367(9514):945-7. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(06)68388-8/abstract. Accessed March 7, 2016
3/2006
New drugs for tuberculosis: current status and future prospects
Publication: O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med. 2005 Jun;26(2):327-40, vii. http://www.sciencedirect.com/science/article/pii/S0272523105000158. Accessed March 7, 2016
6/2005
Mycobacterium tuberculosis: new tricks for an old bug
Publication: Spigelman M, Ma Z. Mycobacterium tuberculosis: new tricks for an old bug. Expert Rev Anti Infect Ther. 2004 Aug;2(4):467-9.https://www.researchgate.net/publication/8234528_Mycobacterium_tuberculosis_New_tricks_for_an_old_bug. Accessed March 7, 2016
8/2004